A Bridging Trial to Compare the PK Profile When Glepaglutide is Administered Via Vial/Syringe Versus Autoinjector.
Status:
Completed
Trial end date:
2021-06-10
Target enrollment:
Participant gender:
Summary
This is an open-label, randomized, single center, 2-treatment, 3-period, 3-sequence
reference-replicated, crossover trial in healthy subjects to compare the PK of glepaglutide
(ZP1848) after a single SC administration by vial/syringe and by autoinjector.